Payment overview · 2025
General Payments
$849.05
48 reported records · 16 companies
Healthcare provider profile · identity verified
Joseph Matthew Chase, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STOW, OH · NPI 1508858358
Verified facts
What the public records show
CMS Open Payments records show Joseph Matthew Chase, M.D. received $849.05 in general payments during 2025 across 48 reported records.
ABBVIE INC. accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 270 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $174.05 | 20.5% | 11 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $148.26 | 17.5% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $113.16 | 13.3% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.05 | 8.5% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $58.64 | 6.9% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.24 | 5.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.40 | 4.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.47 | 3.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.06 | 3.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.67 | 3.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.87 | 2.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.41 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.92 | 2.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.00 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.90 | 1.6% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $4.95 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $849.05 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $187.66 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $113.16 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $100.83 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $81.01 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $72.05 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $68.15 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $58.64 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $50.24 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.01 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.47 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.06 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.06 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $31.14 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $11.17 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $4.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 270 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
270 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 629 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 272 | 64 |
| Eliquis | Apixaban | 270 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 58 |
| Lisinopril | Lisinopril | 202 | 55 |
| Gabapentin | Gabapentin | 197 | 37 |
| Omeprazole | Omeprazole | 187 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 49 |
| Furosemide | Furosemide | 185 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 46 |
| Donepezil Hcl | Donepezil Hcl | 160 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 29 |
| Sertraline Hcl | Sertraline Hcl | 132 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 28 |
| Metformin Hcl Er | Metformin Hcl | 121 | 34 |
| Simvastatin | Simvastatin | 117 | 24 |
| Losartan Potassium | Losartan Potassium | 116 | 31 |
| Memantine Hcl | Memantine Hcl | 109 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 22 |
| Potassium Chloride | Potassium Chloride | 96 | 20 |
| Finasteride | Finasteride | 86 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 26 |
| Trazodone Hcl | Trazodone Hcl | 82 | 22 |
| Metformin Hcl | Metformin Hcl | 81 | 17 |
| Montelukast Sodium | Montelukast Sodium | 80 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 18 |
| Allopurinol | Allopurinol | 76 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 33 |
| Famotidine | Famotidine | 69 | 15 |
| Latanoprost | Latanoprost | 69 | suppressed |
| Myrbetriq | Mirabegron | 68 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 66 | suppressed |
| Carvedilol | Carvedilol | 66 | 18 |
| Jardiance | Empagliflozin | 66 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 42 |
| Synthroid | Levothyroxine Sodium | 57 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 27 |
| Celecoxib | Celecoxib | 50 | 16 |
| Ozempic | Semaglutide | 50 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 11 |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Spironolactone | Spironolactone | 45 | suppressed |
| Torsemide | Torsemide | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Entresto | Sacubitril/Valsartan | 44 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 44 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 42 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 40 | 14 |
| Lovastatin | Lovastatin | 39 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Prednisone | Prednisone | 34 | 22 |
| Azithromycin | Azithromycin | 33 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Meloxicam | Meloxicam | 32 | 14 |
| Alprazolam | Alprazolam | 31 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 29 | suppressed |
| Lorazepam | Lorazepam | 28 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 16 |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 12 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Carbidopa | Carbidopa | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 11 |
| Pregabalin | Pregabalin | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $849.05 · 48 records | ABBVIE INC. | AREXVY, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, Fibroscan, INSPIRE, JARDIANCE, Korlym, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, VYALEV, Veozah, Wegovy, XIFAXAN, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error